Title : Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.

Pub. Date : 2021 Feb 26

PMID : 33637050






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A higher proportion of patients on DTG achieved VS compared to PI/rs [Range:33.1%(13.6,50.4)-45.3%(24.1,61.6)] and RAL [16.7%(3.3,31.2)] in patients with VL > 100,000 copies/mL at baseline, and similar VS was achieved in patients with CD4+ <= 200 cells/muL at baseline. dolutegravir CD4 molecule Homo sapiens
2 DTG also achieved greater increase in CD4+ cells from baseline compared to EFV [32.6(10.7,54.7)], ritonavir-boosted darunavir [DRV/r:25.7(3.6,48.1)] and BIC [24.7(1.5,47.7)]. dolutegravir CD4 molecule Homo sapiens